Market closedNon-fractional
Cullinan Oncology/CGEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cullinan Oncology
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Ticker
CGEM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
85
Website
cullinantherapeutics.com
CGEM Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$3.14
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Financial strength
Current ratio
20.329
Quick ratio
19.75
Long term debt to equity
0.432
Total debt to equity
0.744
Management effectiveness
Return on assets (TTM)
-22.15%
Return on equity (TTM)
-29.47%
Valuation
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-6.9
Growth
Earnings per share change (TTM)
-320.66%
3-year earnings per share growth (CAGR)
25.84%
What the Analysts think about CGEM
Analyst Ratings
Majority rating from 9 analysts.
CGEM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$37M
55.88%
Profit margin
0.00%
NaN%
CGEM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.91
-$0.54
-$0.86
-
Expected
-$0.97
-$0.92
-$0.96
-$0.99
-$0.73
Surprise
-15.46%
-1.27%
-43.83%
-13.10%
-
CGEM News
AllArticlesVideos
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
GlobeNewsWire·2 months ago
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
GlobeNewsWire·2 months ago
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cullinan Oncology stock?
Cullinan Oncology (CGEM) has a market cap of $1.1B as of July 26, 2024.
What is the P/E ratio for Cullinan Oncology stock?
The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of July 26, 2024.
Does Cullinan Oncology stock pay dividends?
No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Cullinan Oncology dividend payment date?
Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Cullinan Oncology?
Cullinan Oncology (CGEM) does not currently have a Beta indicator.
Buy or sell Cullinan Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.